JF
AKBA icon

Jump Financial’s Akebia Therapeutics AKBA Stock Holding History

Jump Financial’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-355,843
Closed -$971K – 1907
2025
Q3 		$971K Buy
+355,843
New +$1.18M 0.01% 1027
2024
Q2 		– Sell
-41,920
Closed -$76.7K – 1766
2024
Q1 		$76.7K Buy
+41,920
New +$67K ﹤0.01% 1812
2021
Q4 		– Sell
-152,300
Closed -$439K – 1346
2021
Q3 		$439K Sell
152,300
-80,703
-35% -$230K 0.03% 522
2021
Q2 		$883K Buy
233,003
+99,101
+74% +$334K 0.09% 303
2021
Q1 		$453K Sell
133,902
-21,681
-14% -$78.1K 0.04% 441
2020
Q4 		$435K Sell
155,583
-44,917
-22% -$131K 0.07% 434
2020
Q3 		$503K Buy
+200,500
New +$1.76M 0.1% 327

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jump Financial's AKBA Position: Q4 2025 in Review

Jump Financial sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 355,843 shares — an estimated $971K sold.

Jump Financial first reported a position in AKBA in Q3 2020 and held it in 7 quarters. The position peaked at $971K in Q3 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • Jump Financial reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jump Financial sold 355,843 Akebia Therapeutics shares in Q4 2025, an estimated $971K.
  • Jump Financial first reported a position in Akebia Therapeutics in Q3 2020 and held it in 7 quarters.
  • Jump Financial's Akebia Therapeutics position peaked at $971K in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Jump Financial's 13F filing for Q4 2025, filed 17 Feb 2026.